Neurology News with information about conditions, treatments, current studies and breakthroughs.
Myositis
What is myositis? Myositis is a group of rare autoimmune diseases characterized by inflammation and damage to skeletal muscles, which [...]
Pseudobulbar affect (PBA)
What is pseudobulbar affect? Pseudobulbar affect (PBA) is a neurological condition characterized by episodes of uncontrolled, sudden and frequent outbursts [...]
Electromyogram (EMG)
What is Electromyogram? Electromyogram (EMG) is a diagnostic test used to evaluate the health of muscles and the nerve cells [...]
Nerve Conduction Study
What is a nerve conduction study? Nerve conduction study (NCS) is a diagnostic test used to evaluate the function of [...]
Physical Therapy for Carpal Tunnel Syndrome
Physical therapy can be an effective treatment for carpal tunnel syndrome by improving strength and flexibility in the affected wrist [...]
How to Prevent Loneliness and Social Isolation
Feeling lonely and isolated are bad for your health. Watch the video below for tips on how to stay connected [...]
- Exposure to Air Pollutants and Lewy Body and Parkinson Disease–Related Dementias June 12, 2026New JAMA Publication! Congratulations to Dimitry S. Davydow, MD, MPH, Gregory M. Pontone, MD, MHS, Michael S. Okun, MD, and Melissa J. Armstrong, MD on their publication “Exposure to Air Pollutants and Lewy Body and Parkinson Disease–Related Dementias,” which appears in JAMA Open Network. Long-term exposure to common air pollutants may increase the risk of developing Parkinson’s disease-related dementia and Lewy body dementia, according to…
- Real-World Safety and Effectiveness of 24-Hour Foslevodopa/Foscarbidopa in Parkinson’s Disease: ROSSINI Study 6-Month Interim Results June 10, 2026Congratulations Dr. Irene Malaty Dr. Malaty research “Real-World Safety and Effectiveness of 24-Hour Foslevodopa/Foscarbidopa in Parkinson’s Disease: ROSSINI Study 6-Month Interim Results,” was published in the May 2026 issue of Neurology and Therapy. Abstract Foslevodopa/foscarbidopa (LDp/CDp) is a nonsurgical 24-h continuous subcutaneous infusion for patients with advanced Parkinson’s disease (aPD) and motor fluctuations uncontrolled on…
- Diffusion MRI and α‐Synuclein Seed Amplification Status in Parkinson’s Disease June 8, 2026New Publication! Congratulations to Drs. Melissa J Armstrong, Nikolaus R. McFarland, Michael Okun and David Vaillancourt on the publication of “Diffusion MRI and α‐Synuclein Seed Amplification Status in Parkinson’s Disease,” which appears in the May edition of Annals of Neurology. Abstract Objective Positive α‐synuclein seed amplification assay (SAA) is a biomarker found in most people…
- Unveiling Reporting & Representation of Race and Ethnicity in Acute Interventional Neurology Trials: A Systematic Review June 5, 2026Congratulations on your new publication! Congratulations to Hector David Meza Comparan, Luciola Frota, Michael Mathelier, Carolina Maciel and Katharina Busl on the publication of “Unveiling Reporting & Representation of Race and Ethnicity in Acute Interventional Neurology Trials: A Systematic Review,” which appears in the April 8th edition of Neurology. Abstract Objective: To evaluate the extent and…
Get Social